PTEN and PI3K/AKT in non-small-cell lung cancer. (Q38629644)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

review article

0 references

title

PTEN and PI3K/AKT in non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase

29 February 2020

main subject

0 references

author

Maria Luisa Cañadas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Cristina Pérez-Ramírez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Miguel Ángel Molina

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

María José Faus-Dáder

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Miguel Ángel Calleja-Hernández

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

10 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1843-1862

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Alternative splicing of the human PTEN/MMAC1/TEP1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The role of phosphoinositide 3-kinase lipid products in cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Role of phosphatidylinositol kinase in PDGF receptor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Allelotype and replication error phenotype of small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Comparative allelotype of early and advanced stage non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Allelic loss on chromosome 10q in human lung cancer: association with tumour progression and metastatic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mutation and cancer: statistical study of retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PIK3CA mutation and amplification in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PIK3CA mutations and copy number gains in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Will the real Cowden syndrome please stand up: revised diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phosphorylation of the PTEN tail regulates protein stability and function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Direct identification of PTEN phosphorylation sites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The phosphatase PHLPP controls the cellular levels of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Induction of NF-kappaB by the Akt/PKB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The activation of Akt/PKB signaling pathway and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The life of a cell: apoptosis regulation by the PI3K/PKB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

A unifying model for mTORC1-mediated regulation of mRNA translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

An expanding role for mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The expanding TOR signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

mTOR and cancer: many loops in one pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Functional analysis of PIK3CA gene mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

AKT1(E17K) in human solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Pten is essential for embryonic development and tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Pten in stromal fibroblasts suppresses mammary epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

21 January 2018

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Nitric oxide mediates ultrasound-induced hypoxia-inducible factor-1alpha activation and vascular endothelial growth factor-A expression in human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Regulation of angiogenesis by glycogen synthase kinase-3beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Lack of PTEN sequesters CHK1 and initiates genetic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Mechanistic insights into maintenance of high p53 acetylation by PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN and the PI3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

Loss of heterozygosity in sporadic primary cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.122

21 January 2018

Identifiers

DOI

10.2217/PGS.15.122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26555006%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference